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Abstract
The binding of peptide fragments of antigens to class II MHC proteins is a crucial step in initiating a helper T cell immune
response. The discovery of these peptide epitopes is important for understanding the normal immune response and its
misregulation in autoimmunity and allergies and also for vaccine design. In spite of their biomedical importance, the high
diversity of class II MHC proteins combined with the large number of possible peptide sequences make comprehensive
experimental determination of epitopes for all MHC allotypes infeasible. Computational methods can address this need by
predicting epitopes for a particular MHC allotype. We present a structure-based method for predicting class II epitopes that
combines molecular mechanics docking of a fully flexible peptide into the MHC binding cleft followed by binding affinity
prediction using a machine learning classifier trained on interaction energy components calculated from the docking
solution. Although the primary advantage of structure-based prediction methods over the commonly employed sequence-
based methods is their applicability to essentially any MHC allotype, this has not yet been convincingly demonstrated. In
order to test the transferability of the prediction method to different MHC proteins, we trained the scoring method on
binding data for DRB1*0101 and used it to make predictions for multiple MHC allotypes with distinct peptide binding
specificities including representatives from the other human class II MHC loci, HLA-DP and HLA-DQ, as well as for two
murine allotypes. The results showed that the prediction method was able to achieve significant discrimination between
epitope and non-epitope peptides for all MHC allotypes examined, based on AUC values in the range 0.632–0.821. We also
discuss how accounting for peptide binding in multiple registers to class II MHC largely explains the systematically worse
performance of prediction methods for class II MHC compared with those for class I MHC based on quantitative prediction
performance estimates for peptide binding to class II MHC in a fixed register.
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Introduction
The binding of peptide fragments of extracellular proteins to
class II MHC is a critical step in activating a helper T cell-
mediated immune response. The discovery of such peptide
epitopes has several important biomedical applications. For
example, peptide epitopes from pathogen antigens that bind to
multiple MHC allotypes present in a population are needed for
developing vaccines with broad protective immunity. Also, class
II MHC has a role in autoimmune diseases, as specific class II
MHC alleles have been found to be either positively or negatively
associated with many autoimmune diseases including type 1
diabetes [1,2,3], rheumatoid arthritis [4], multiple sclerosis [5,6],
celiac disease [7], and narcolepsy [8,9]. Peptide binding
specificities for risk-associated alleles could help identify new
causative autoantigens or help investigate mechanistic hypotheses
such as competitive capture by alternative binding registers
[10,11]. They can also help find possible mechanisms for the
protective effects of other alleles. In addition, such information
can guide the search for therapeutic inhibitors that block
autoantigen binding by the responsible MHC allotype. Finally,
class II epitopes show promise as an immunotherapy for the
treatment of allergies [12,13,14,15,16,17] so that information on
these epitopes could potentially be used to design effective allergy
therapies.
In spite of these promising potential applications, experimental
information on peptide-MHC binding specificities is limited in
coverage since class II MHC is highly polymorphic and the space
of peptide sequences is enormous. Computational methods can
assist by predicting peptide-MHC binding affinities that can later
be experimentally validated. Such prediction methods broadly fall
into two categories, sequence-based and structure-based, each
with complementary advantages and disadvantages. Sequence-
based methods are fast but require a large quantity of
experimental binding data for the MHC type of interest. Although
slower, structure-based methods are more general and can
potentially be applied to any class II MHC type, including
experimentally uncharacterized ones.
Sequence-based methods use patterns in peptide sequences with
known binding affinities to a particular MHC allotype in order to
predict binding affinities. Such methods have been developed for
peptide binding to class II MHC using a wide variety of fitting
techniques including partial least squares (PLS) [18,19], Gibbs
sampling [20], linear programming [21], Support Vector Ma-
chines (SVMs) [22,23,24], kernel methods [25], non-linear
optimization with a regularization penalty [26], or a combination
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predictions for closely related MHC types not used for training
[28,29,30], basically by interpolating between prediction models
for the few experimentally characterized MHC types based on
limited structural information about shared MHC residues or
pockets. However, no sequence-based method can make predic-
tions for an MHC allotype that is significantly different from
experimentally characterized MHC allotypes so that it does not
share most of its specificity-determining residues. A survey of the
available experimental peptide-MHC binding data from the
Immune Epitope Database (IEDB) [31] shows that only a minute
fraction of the hundreds to thousands of MHC allotypes for each
locus have sufficient experimental data to train a sequence-based
model. For example, considering human MHC, only about 14
HLA-DR allotypes, 5 HLA-DP allotypes, and 5 HLA-DQ
allotypes currently have sufficient experimental data. These data
permit the construction of multi-type sequence-based prediction
models that cover of the majority of known HLA-DR allotypes but
only a small fraction of HLA-DP and HLA-DQ allotypes [30].
Structure-based prediction methods, such as the one described
here, can address this shortcoming and potentially make
predictions for any MHC allotype based on the universal physical
principles of intermolecular interactions. Such methods can be
used to suggest novel peptide epitopes for under-characterized or
uncharacterized MHC allotypes for subsequent experimental
testing.
In contrast with sequence-based methods, comparatively little
work has been done to explore structure-based methods for
predicting peptide binding affinities to class II MHC. Davies et al.
2003 [32] built homology models of DRB1*0301, DRB1*0401,
and DRB1*1101 using a DRB1*0101 template structure and
docked peptides into these MHC models using simulated
annealing optimization with the AMBER force field in explicit
water. The resulting peptide-MHC interaction energy of the
complex was then used to discriminate binders from non-binders.
The study reported prediction accuracies comparable with the
contemporaneous SYFPEITHI and TEPITOPE sequence-based
methods, as evaluated for small test sets of 22–30 peptides.
Another study by Schafroth and Floudas [33] docked individual
amino acids into five binding pockets in DRB1*0101 and
compared the predicted qualitative binding preferences of each
pocket with experimental results. In a more recent study by Tong
et al. [34], the authors docked peptides into a DQA1*0301/
DQB1*0302 MHC structure from the Protein Data Bank (PDB)
using a four-step procedure. The docking procedure consisted of
rigid body docking of terminal core fragments, central loop
closure, constrained all-atom refinement of the core segment, and
extension of the core segment. Peptide binding affinities were
predicted using a linear combination of the hydrophobic, entropic,
and electrostatic components of the interaction free energy with
optimized weights. Finally, during the course of this work, a new
study by Zhang et al. [35] appeared, which describes a comparison
of three different structure-based prediction methods using a
common data set of peptides binding to DRB1*0101. The three
methods were (1) complex structure prediction using MODEL-
LER and scoring using a statistical residue pair potential, (2)
molecular dynamics simulation in explicit water of all possible
single residue mutants of a single peptide epitope binding the
MHC followed by derivation of a position specific scoring matrix
(PSSM) based on the average interaction energy with Poisson-
Boltzmann surface area (PBSA) implicit solvation over 100 MD
snapshots, and (3) a PSSM derived from the number of
intermolecular residue contacts in available X-ray structures of
peptide-DRB1*0101 complexes. The three methods yielded
comparable AUC values of 0.682, 0.667, and 0.621, respectively.
While the first two methods are potentially applicable to other
MHC allotypes, the latter method requires a sufficient number of
experimental peptide-MHC structures for the allotype of interest
in order to derive the PSSM and so is likely limited to DRB1*0101
at present. One novel aspect of our study, not addressed by these
previous studies, is a demonstration of the generality of the
prediction method by applying it to a wide variety of MHC
allotypes with distinct peptide binding specificities. This is
arguably the single most important advantage of structure-based
methods over sequence-based ones and so is crucial to test.
The binding of peptides to class I and class II MHCs differ in
several respects. Class I MHC binds short peptide fragments (,8–
11 residues), generally derived from intracellular proteins, whereas
class II MHC binds longer fragments (,15–25 residues) of
extracellular proteins. The reason for this difference is evident
from available X-ray structures of peptide-MHC complexes. The
class I MHC peptide binding cleft is closed at both ends and binds
the peptide partly through conserved hydrogen bonds to the
peptide backbone at the N- and C-termini. Thus the peptide
backbone assumes a conserved conformation at the termini and
bulges out from the cleft in the center. In contrast, the class II
MHC peptide-binding cleft is open at both ends so that the
peptide binds in an extended polyproline II conformation so that
both termini can extend beyond the cleft. The core 9-mer peptide
segment contacting the MHC assumes a common backbone
conformation due to conserved hydrogen bonds to backbone
atoms along its entire length. For both MHC classes, the
conserved hydrogen bond interactions of the MHC with the
peptide backbone contribute to high affinity binding for a large
number of different peptides while interactions with the peptide
side chains determine the characteristic binding specificity of each
MHC allotype.
In accordance with these differences, the prediction strategies
for class II MHC differ from those for class I MHC. Most
importantly, all possible binding registers of the peptide, defined
by the core 9-mer segment contacting the MHC, must be
considered in a class II MHC prediction method. Furthermore,
the experimental data only provides the overall peptide binding
affinity and not information on the predominant binding register.
Our method accounts for this ambiguity by docking all possible 9-
mer segments and predicting the peptide as a binder if any
segment is predicted to bind strongly, and otherwise as a non-
binder. A machine learning classifier is used to identify whether or
not each 9-mer segment is a binder based on interaction energy
components calculated from the docking solution. Because
experimental data on the binding registers is unavailable, the
classifier is trained on a balanced set of 9-mer binders and non-
binders predicted using a sequence-based prediction method [26].
Also, in order to reduce costly conformational sampling and obtain
a native-like peptide backbone conformation, the peptide
backbone is restrained to be near the native conformation during
the docking simulation.
We first tested and optimized the peptide-MHC docking
procedure by comprehensive self-docking and cross-docking
followed by comparison of the results with all available human
and murine peptide-MHC complex structures in the PDB. Next
we trained the machine learning classifier on binding data for
DRB1*0101 and made predictions for peptide binding to multiple
dissimilar MHC allotypes in order to test the transferability of the
prediction method. We also assessed the accuracy of the prediction
method on the separate task of predicting predominant peptide
binding registers and compared the results with known binding
registers inferred from available X-ray structures of peptide-MHC
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estimates of the prediction performance for peptides binding class
II MHC in a particular fixed register and found that the calculated
values were similar to that previously obtained for peptide binding
to class I MHC, in which only one binding mode is possible. This
provides an explanation for the previously noted overall lower
accuracy of prediction methods for peptide binding to class II
MHC compared to those for class I MHC. Finally, we discuss the
implications of the results for general prediction of peptide-MHC
binding affinities and possible future improvements.
Methods
Overview of the structure-based prediction procedure
The goal of the prediction procedure is to determine whether a
particular peptide is a binder (IC50 ,500 nM) or a non-binder
(IC50 $500 nM) for the MHC allotype of interest. This is
accomplished by three steps: (1) docking of all possible 9-mer core
segments from the peptide into the MHC protein to predict the
structures of the bound complexes, (2) machine-learning based
scoring to predict the 9-mer binding affinities based on the
structures from step (1), and (3) calculating the final binding score
as the maximum score over all 9-mer segments.
Peptide-MHC docking
The docking method is similar to that previously employed for
class I MHC [36], with the main difference being the use of
modified peptide backbone constraints. First, an all-atom flexible
model of the peptide with neutral N- and C-terminal groups was
docked into a grid potential representation of the MHC peptide-
binding cleft. The MHC structure from the highest resolution
peptide-MHC structure in the PDB was used (see Tables 1 and
2). Grid potentials have the advantage of being dramatically more
computationally efficient than all-atom sampling of MHC side
chains while allowing implicit flexibility through smoothed van der
Waals interactions that allow limited steric clashes. Furthermore,
an alignment of peptide-MHC complex structures for the MHC
allotype with the most structures, HLA-DRB1*0101, shown in
Figure 1, demonstrates that the MHC side chains contacting the
peptides undergo little conformational change upon binding
different peptides. While some conformational differences in the
MHC peptide-binding cleft must occur in order to accommodate
the binding of different peptides, this limited experimental
evidence suggests that these differences are relatively small.
Docking was performed using biased-probability Monte Carlo
global optimization [37] of a physical energy function using the
ICM program (Molsoft LLC). The energy function is a sum of the
intramolecular all-atom energy of the peptide calculated using the
ECEPP/3 force field [38,39,40], the interaction energy of the
peptide and the MHC calculated using grid potentials, and a
harmonic restraint potential on the peptide backbone. Five types
of grid potentials were used for the non-hydrogen atom van der
Waals (ECvw), hydrogen atom van der Waals (EHvw), hydrogen
bond (Ehb), electrostatics (Eel), and hydrophobic (Ehp) components
of the peptide-MHC interaction energy. These potentials were
precomputed on a rectilinear grid with 0.5 A ˚ spacing containing
the peptide and peptide-binding domain of the MHC. Potential
values at arbitrary points were calculated using linear interpolation
of values at the nearest grid points. ECvw and EHvw were calculated
as the smoothed van der Waals (vdW) interaction energy, with a
cutoff value Emax
vw =3 kcal/mol at zero separation, between
corresponding probe atoms at grid points and the MHC protein
[41]. The smooth vdW potential further reduces the extreme
sensitivity of the vdW energy to small conformational changes.
The hydrogen bond and hydrophobic energies were calculated as
described in Ref. [41] and the electrostatic energy was calculated
using a distance-dependent dielectric e=4r. Weights multiplying
the grid potentials were optimized to yield the lowest average
RMSD from among the 5 lowest energy docking solutions
accumulated during each Monte Carlo run. All possible
combinations of weight values between 0.0 and 5.0 in 0.5
increments were tried. As expected, the optimal weights were
similar to those we previously obtained for peptide-class I MHC
docking using a different optimization protocol [36]. The
intramolecular peptide energy (Epeptide) was calculated with the
ECEPP/3 force field and included a truncated vdW potential with
Emax
vw =7 kcal/mol, the distance-dependent dielectric electrostatic
term, hydrogen bond, torsional potentials, and a side chain
entropic term proportional to the fractional SASA [37]. Finally, a
harmonic restraint potential,
Erestraint~w
X N
i~1
Dri{r
template
i D
2
,
between corresponding peptide backbone atoms in the modeled
peptide and those in the template peptide-MHC complex
structure was used to limit the conformational sampling space,
and so speed up convergence, while insuring that the final docking
solution has a backbone conformation similar the conserved
conformation observed in X-ray structures. All peptide backbone
atoms between P-1 to P9 were included in the restraint potential
based on the extent of the conserved backbone structure observed
in X-ray structures. The restraint weight value w=1.0 kcal/
(mol A ˚ 2) was found to yield the best cross-docking results and so
used in all subsequent docking simulations. The final energy
function used for docking was then
Etotal~ECvwzEHvwz0:5Ehbz5:0Eelz2:0EhpzEpeptidezErestraint:
The ICM Monte Carlo simulations were run for a total 5610
7
function calls using a temperature parameter of 700K. This
required an average simulation time of approximately 10 hours on
a 3 GHz Opteron processor.
All-atom structure optimization and interaction energy
evaluation
The lowest energy docking solutions were then subjected to all-
atom structure optimization using a more accurate physical energy
function and the interaction energy components of the final
structure used as input to the machine learning scoring method.
First the MHC protein was replaced by an all-atom model and the
docking solution structure refined by local optimization of an all-
atom energy function that included ECEPP/3 energy terms (vdW
smoothed with Emax
vw =7 kcal/mol, hydrogen bond, and torsion
potentials), generalized Born solvation electrostatics with ECEPP/
3 atomic charges and ein=4, a non-polar solvation term
proportional to the SASA with constant 0.012 kcal/(mol A ˚ 2), a
side chain entropy term (described above), and the same peptide
backbone restraint potential used for grid potential docking. The
goal of this procedure was not to improve the docked structure, as
local optimization led to only minor variations in the initial grid
potential docking solution, but rather to reduce steric clashes and
so yield accurate values for the interaction energy components
using a more detailed all-atom model of the MHC protein and a
more realistic implicit solvation model.
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The peptide binding affinities were predicted by first predicting
whether or not each 9-mer fragment binds; if at least one was
predicted to bind then the peptide was classified as a binder,
otherwise it was classified as a non-binder. A Random Forest
binary classifier [42] trained on interaction energy components
and 20 residue type counts was used to predict whether or not
each 9-mer fragment bound to the MHC allotype of interest. The
interaction energy components included van der Waals, hydrogen
bond, electrostatics, non-polar solvation, and entropy contribu-
tions calculated from the final refined docking solution as the
difference in these energy terms between the peptide-MHC
complex and the isolated peptide and MHC in their bound
conformations. In principle, the optimized conformation of the
isolated peptide could be used, however this did not improve the
binding affinity predictions (data not shown). Two empirical
residue potentials, the Betancourt-Thirumalai contact potential
[43] and DFIRE-SCM side chain centroid potential [44], were
also included in the input data. Both potentials were included since
their correlation was quite low (Pearson correlation coeffi-
cient=0.45 for DRB1*0101 data) so that they provided largely
independent information. The DFIRE-SCM potential was refit
using the latest non-redundant structures from the culled PDB
data set [45] with 30% sequence identity, 2.0 A ˚ resolution, and
0.25 R-factor cutoffs. The inclusion of residue type counts can be
Table 1. Peptide – human class II MHC docking results.
Peptide-MHC complex structure Docked peptide sequence
Backbone
RMSD (A ˚)
All-atom
RMSD (A ˚)
Core
backbone
RMSD (A ˚)
Core all-atom
RMSD (A ˚)
Contacting
peptide residue
numbers
DRB1*0101 (1KLU)
1KLU* ELIGTLNAAKVPAD 0.26 1.21 0.23 0.75 21–1,3,4,6–10
1AQD SDWRFLRGYHQY 0.86 2.34 0.86 2.58 0–5,7–10
2G9H PKYVKQNTLKLA 0.92 1.53 0.98 1.62 21–7,9,10
1KLG ELIGILNAAKVP 0.29 1.67 0.30 0.90 21–1,3,4,6–10
1SJE PEVIPMFSALSE 0.75 2.13 0.61 1.84 21–10
1T5W AAYSDQATPLLL 0.88 1.21 0.94 1.28 21–4,6–10
2FSE AGFKGEQGPKGE 0.86 2.17 0.81 1.91 1,2,4,7,10
DRB1*0301 (1A6A)
1A6A* SKMRMATPLLMQ 0.26 0.97 0.23 0.76 21–10
DRB1*0401 (1J8H)
1J8H* PKYVKQNTLKLA 0.39 0.56 0.28 0.51 21–10
DRB1*1501 (1BX2)
1BX2* PVVHFFKNIVTP 0.24 0.78 0.21 0.83 21–6,9,10
DRB3*0101 (2Q6W)
2Q6W* AWRSDEALPLG 0.20 0.62 0.21 0.63 0–9
DRB3*0301 (3C5J)
3C5J* QVIILNHPGQIS 0.32 1.56 0.22 1.16 21,1–6,8–10
DRB5*0101 (1FV1)
1FV1* HFFKNIVTPRTP 0.34 1.55 0.24 0.94 0–4,6
1H15 GVYHFVKKHVHE 0.32 0.49 0.29 0.50 0–4,6
DQA1*0501/DQB1*0201 (1S9V)
1S9V* LQPFPQPELPY 0.27 0.88 0.22 0.30 21–4,6,7,9
DQA1*0102/DQB1*0602 (1UVQ)
1UVQ* MNLPSTKVSWAA 0.26 0.44 0.26 0.26 21–4,6–10
DQA1*0301/DQB1*0302 (2NNA)
2NNA* SGEGSFQPSQEN 0.30 1.15 0.22 0.64 21,1,3–10
1JK8 LVEALYLVCGER 0.90 1.73 0.56 0.74 0–7,9,10
DPA1*0103/DPB1*0201 (3LQZ)
3LQZ* RKFHYLPFLPST 0.15 1.04 0.12 1.13 0–4,6,7,9,10
Self-docking median RMSDs 0.26 0.97 0.22 0.75
Cross-docking median RMSDs 0.86 1.70 0.71 1.45
Self-docking results are indicated by asterisks. The PDB ID for the MHC structure used in docking is shown in parentheses for each allotype. All-atom RMSDs were
calculated for all non-hydrogen atoms in the peptide residues that contact the MHC in the experimental structure. The core RMSDs include only peptide residues P1–P9
(underlined in the peptide sequence) whereas the other values include all simulated residues from P-1 to P10. The highest resolution MHC structure, in parentheses, was
used for each allotype. The RMSD values were calculated after aligning the MHC structures. Consecutive residue numbers in the last column are denoted by a numeric
range.
doi:10.1371/journal.pone.0014383.t001
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energy for the isolated peptide, in which each residue makes an
additive contribution based on its type. Finally, we note that,
unlike sequence-based models, no properties that depend on the
residue positions (P1–P9) are used. This would be expected to ruin
the transferability of the prediction model to multiple highly
dissimilar MHC types, which is the primary motivation for the
structure-based model.
As mentioned above, one challenge of peptide binding affinity
predictions for class II MHC is that only the binding affinities and
not the binding registers are generally known experimentally. This
was solved by training the Random Forest classifier on sequence-
based predictions for individual 9-mer fragments. Binary predic-
tions (binder/non-binder) were made using our RTA method [26]
for all 9-mers in the set of 1725 DRB1*0101 peptide sequences
using the same 500 nM IC50 cutoff as used for complete peptides.
In order to construct a balanced training data set, input data for all
9-mer fragment binders and an equal number of randomly
selected non-binders were included. A Random Forest with 2000
trees and 5 variables/tree was used since it yielded the best
prediction performance for DRB1*0101, as assessed on out-of-bag
training set data. Because the two Random Forest parameters
were selected using training set data alone, prediction results for
the test sets are expected to accurately estimate the prediction
performance for novel peptides and MHC allotypes. Because
Random Forest performance converges with an increasing
number of trees [42], the minimum number of trees required for
a reasonably converged result was chosen for computational
speed. Also, as previous observed [42], we found that the
prediction accuracy did not change much as the remaining model
parameter, the number of variables per tree, was varied.
Experimental peptide binding affinity data
Experimental peptide-MHC binding affinity data were used for
training the scoring method and evaluating the prediction
performance. Binding data for DRB1*0101, DQA1*0501/
DQB1*0201, H2-IA
b, and H2-IA
d were downloaded from the
Immune Epitope Database (IEDB) [31]. All quantitative data
obtained by either radioactivity or fluorescence competition
binding assays were included. The DPA1*0103/DPB1*0201
binding data were obtained from Ref. [46] and included known
epitopes as well as a set of overlapping peptides spanning Phleum
pratense antigens. Single residue mutation data, employed in the
SAAS analysis, was excluded due to its limited sequence diversity.
Finally, data for similar peptide sequences with .40% sequence
identity were removed using CD-HIT [47] in order to obtain non-
redundant data sets. Also any sequences in the DRB1*0101
training set with 100% identity to any sequence included in the
other test sets were removed. Even though the binding affinities of
a peptide to two such different MHC allotypes are expected to be
Table 2. Peptide – murine class II MHC docking results.
Peptide-MHC
complex
structure Docked peptide sequence
Backbone
RMSD (A ˚)
All-atom
RMSD (A ˚)
Core backbone
RMSD (A ˚)
Core all-atom
RMSD (A ˚)
Contacting peptide
residue numbers
H2-IA
b (1MUJ)
1MUJ* PVSKMRMATPLLMQA 0.25 0.88 0.26 0.58 21–10
1LNU FEAQKAKANKAVD 0.70 1.83 0.74 1.96 21–10
H2-IA
d (2IAD)
2IAD* see footnote
1IAO ISQAVHAAHAE 0.48 1.58 0.42 1.03 1–10
H2-IA
g7 (1ES0)
1ES0* YEIAPVFVLLEY 0.20 2.44 0.21 0.29 21–10
1F3J MKRHGLDNYRGY 0.83 1.79 0.75 1.27 21–2,4–8,10
3CUP KKMREIIGWPGG 0.88 2.24 0.87 1.62 21–5,7,8
H2-IA
k (1IAK)
1IAK* STDYGILQINSR 0.33 1.18 0.33 1.03 21–2,4–10
H2-IA
u (1K2D)
1K2D* SRGGASQYRPSQ 0.17 0.73 0.17 0.60 0,3–10
H2-IE
k (1FNG)
1FNG* KVITAFNEGLK 0.44 1.34 0.33 1.24 21–6,8,9
1FNE KVITAFNDGLK 0.51 1.29 0.45 1.20 0–4,6–9
1IEB RMVNHFIAEFK 0.83 1.67 0.83 1.70 0–4,6–9
1R5V DLIAYPKAATKF 0.91 2.27 0.77 0.99 21–7,9,10
1KT2 DLIAYLKQATK 0.72 1.38 0.65 1.17 21–4,6–9
1R5W DLIAYFKAATKF 1.43 2.42 0.93 1.20 21–7,9,10
1KTD DLIAYLKQASAK 1.50 3.06 0.61 1.14 21–10
Self-docking median RMSDs 0.25 1.18 0.26 0.60
Cross-docking median RMSDs 0.83 1.81 0.75 1.20
See the Table 1 caption for details. The correct peptide sequence for PDB entry 2IAD was unknown since it differs between the reference and the PDB file so docking of
this peptide was not performed.
doi:10.1371/journal.pone.0014383.t002
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in amino acid composition between the training and test sets. The
total numbers of binding data in each set, corresponding to a
particular MHC allotype, are given in Table 3.
Estimating the prediction performance for individual
MHC-binding segments
The usual prediction performance for complete peptides
binding to class II MHC is assessed by directly comparing the
predictions with experimental binding affinity data. We assessed
prediction performance by calculating the area under the Receiver
Operating Characteristic curve (AUC) for predictions on separate
test set data. It is also informative to carry out a similar
performance analysis for the binding prediction of individual 9-
mer segments of the complete peptides since it is known that only
such short segments actually contact the MHC and so contribute
to the overall binding affinity. Because the experimental data only
provides binding affinities of complete peptides and not informa-
tion on which segments bind the MHC, the prediction
performance for segments must be estimated based on a particular
prediction model. Our model predicts that a peptide is a binder if
and only if at least one 9-mer segment is predicted as a binder by
the Random Forest classifier. In order to find the relation between
the prediction performance for the 9-mer segments and the
complete peptides an additional assumption about the number of
binding 9-mer segments in each binding peptide is required. We
examine two possibilities: (1) exactly one binding segment is always
present or (2) either one or two binding segments are present in
each binding peptide. Previous analyses using sequence-based
prediction models by us [26] and others [34] suggest that multiple
segments often contribute to the overall binding affinity however
case (1) is also a reasonable first approximation. Next, we derive
the AUC for segment predictions in these two cases. It should be
emphasized that because of the necessary approximations, the
segment AUC values should only be considered semi-quantitative
estimates. However, as will be seen below, the observation that
they are uniformly higher than the AUC values for complete
peptides is robust and results from combining multiple 9-mer
segment predictions to arrive at a binding prediction for each
peptide.
AUC estimate for predicting 9-mer segments assuming
exactly one binding segment
The AUC is the area under the Receiver Operating
Characteristic (ROC) curve. This curve plots the true positive
rate, tpr, versus the false positive rate, fpr, as the score cutoff is
varied. Our goal then is to express tprseg and fprseg for individual
9-mer segments in terms of tprpep and fprpep for complete peptides
at a common Random Forest score cutoff value. The AUC for 9-
mer segments can then be calculated from these values as the area
under the curve.
We first define the conditional probabilities that a peptide or
fragment is predicted to be a binder (Ppred) or non-binder (Npred),
given that it actually is a binder (Pexp) or non-binder (Nexp). The
fpr is then an estimate of p(Ppred|Nexp) and the tpr is an estimate of
p(Ppred|Pexp). Given that even a single predicted binding fragment
Table 3. Prediction performance for different MHC types using a Random Forest classifier trained on DRB1*0101 peptide binding
data.
AUC
MHC type
Number of
peptides
Number of unique 9-mer
segments Peptide Estimated Core 1 Estimated Core 1–2
DRB1*0101 1725 12858 0.707 0.876 0.854
DQA1*0501/DQB1*0201 236 1783 0.683 0.909 0.900
DPA1*0103/DPB1*0201 219 1602 0.821 0.939 0.925
H2-IA
b 361 2572 0.671 0.875 0.858
H2-IA
d 106 898 0.632 0.707 0.681
The estimated core AUC values assume either exactly one strongly binding 9-mer segment per binding peptide (‘‘Estimated Core 1’’) or either 1 or 2 strongly binding 9-
mer segments with a 70% and 30% probability of occurrence for each strongly binding peptide (‘‘Estimated Core 1–2’’).
doi:10.1371/journal.pone.0014383.t003
Figure 1. Similar HLA-DRB1*0101 peptide-contacting residue
conformations observed in X-ray structures. All HLA-DRB1*0101
peptide-MHC complexes were superimposed by aligning the back-
bones of the MHC peptide binding domains (chain A residues 1–82 and
chain B residues 1–92). MHC chains A and B are shown in red and blue
ribbon representation, respectively. The MHC residues contacting the
bound peptides, shown in stick representation, generally adopt similar
conformations despite contacting different peptides. Much of the small
side chain deviations are due to imperfect alignment of the MHC
backbone atoms. This observation motivates the use of a rigid potential
map representation of the MHC binding cleft in the docking procedure
for efficiency rather than computationally expensive sampling of the
contacting portion of the MHC.
doi:10.1371/journal.pone.0014383.g001
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peptide is a binder we have
fpr 1 ðÞ
pep~pP predDNexp
  
pep~1{pN predDNexp
  
pep
~1{pN predDNexp
   m
frag
~1{ 1{fprfrag
   m,
in which m is the number of 9-mer fragments per peptide. The
average peptide length in the data sets is  L L&15 so that
m~ L L{8~7. Likewise the peptide true positive rate is
tpr 1 ðÞ
pep~pP predDPexp
  
pep~1{pN predDPexp
  
pep
~1{pN predDPexp
  
fragpN predDNexp
   m{1
frag
~1{ 1{tprfrag
  
1{fprfrag
   m{1 hi
Finally, solving for the fragment fpr and tpr gives
fprfrag~1{ 1{fpr 1 ðÞ
pep
   1
m
tprfrag~1{ 1{tpr 1 ðÞ
pep
  
1{fpr 1 ðÞ
pep
   1
m{1
:
These equations are then used to obtain fprfrag and tprfrag at each
cutoff value and so calculate the AUC for predicting individual 9-
mer fragments.
AUC estimate for predicting 9-mer segments assuming
up to two binding segments
A similar argument gives the tpr if exactly two binding segments
are present in binding peptides
tpr 2 ðÞ
pep~1{ 1{tprfrag
   2 1{fprfrag
   m{2 hi
so that the total peptide tpr for either one or two binding segments
in a binder is
tprpep~f1:tpr 1 ðÞ
pepzf2:tpr 2 ðÞ
pep,
in which f1 and f2 are the fractions of binding peptides with exactly
one or two binding segments, respectively. We obtained a rough
estimate of these fractions by counting the number of binding 9-
mer fragments per binding peptide using the sequence-based RTA
model applied to HLA-DRB1*0101 data. This gave the values
f1&0:7 and f2&0:3, which were used in subsequent calculations.
The fpr is the same as in the previous case, i.e. fpr
1 ðÞ
pep~fpr
2 ðÞ
pep. The
quadratic relation between {fprpep, tprpep} and {fprfrag, tprfrag}
may then be solved to obtain expressions for the latter quantities in
term of the former ones. As in the previous case, these relations are
then used to calculate the AUC for predicting individual 9-mer
fragments.
Results
Peptide-MHC docking accuracy
The accuracy of the peptide-MHC docking procedure was
determined by docking peptides from all peptide-MHC complex
structures in the PDB into the representative bound MHC
structure from the highest resolution complex starting with the
peptide in a fully extended conformation. In other words, no a
priori information on the peptide conformation beyond the
backbone restraints described above was used for docking. The
resulting RMSDs of the backbone and all contacting residue atoms
are shown in Table 1 for human MHCs and Table 2 for murine
MHCs. The cross-docking results, in which a peptide is docked
into an MHC structure with a different peptide bound, best reflect
the expected accuracy for docking novel peptides. Self-docking, or
redocking, is considerably easier since the MHC residues in the
peptide-binding cleft are already in the exact bound conformation
and so it does not account for any structural rearrangements of the
MHC peptide-binding cleft. In addition to prediction results for
the full-length peptide, results are also given for the 9-mer core
segment since they are most relevant to the binding affinity
prediction method in which all 9-mer segments are docked.
Figure 2 shows an example of a successful cross-docking solution
Figure 2. Example of a successful peptide-MHC cross-docking solution. This structure was obtained by docking the peptide from PDB entry
1T5W (AAYSDQATPLLL) into a grid potential model of the HLA-DRB1*0101 MHC structure from PDB entry 1KLU, which has a different peptide bound.
The RMSD of the peptide backbone is 0.88 A ˚ and the RMSD of the contacting residues is only 1.21 A ˚ compared with the X-ray structure. The peptide
docking solution is shown in red and the experimental peptide structure is shown in green.
doi:10.1371/journal.pone.0014383.g002
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only 1.21 A ˚ despite the fact that the original MHC structure had a
different peptide bound.
It is apparent from Tables 1 and 2 that almost all peptide side
chains contact the MHC protein (non-hydrogen atom separation
#4A ˚) and so determine binding specificity to varying degrees. In
fact,eachpeptideresiduebetweenP-1andP10contactstheMHCin
multiple structures. This implies that prediction methods which only
account for peptide residues that bind into canonical MHC pockets,
e.g. peptide residues P1, P4, P6, and P9 for HLA-DRB1*0101, may
be missing some peptide-MHC interactions that contribute to
binding. The method described here only includes core residues P1–
P9. This was done because variations in the peptide backbone of
flanking residues makes their prediction moredifficult, as reflected in
the generally higher RMSDs for the longer segments from P-1 to
P10 compared with the 9-mer core segments shown in Tables 1
and 2. Because most peptides have side chain contacts to the MHC
outside of the 9-mer core, a promising area of future study is to
attempt to improve the docking accuracy for full length peptides and
so possibly improve the binding affinity prediction accuracy.
We examined in detail the solution from docking the 1AQD
peptide into the 1KLU MHC structure since it stands out with
significantly higher RMSD than any of the other docking
solutions. The high RMSD was predominantly due to two
misplaced arginine residues at P2 (RMSD=4.1 A ˚) and P5
(RMSD=3.5 A ˚) whose side chains have only minimal interactions
with the MHC in the native structure, with one hydrogen bond
each between the guanidinium group and the MHC backbone,
making it difficult to predict their conformations correctly.
Likewise, the errors in the other docking solutions with high core
RMSDs, namely the 1LNU-1MUJ, 2FSE-1KLU, and 1SJE-
1KLU peptide-MHC complexes, are mainly due to misplaced
large residues at non-pocket positions with minimal MHC
interactions in the native structure: lysine at P8 (3.4 A ˚), lysine at
P2 (3.3 A ˚), and phenylalanine at P5 (3.9 A ˚), respectively. Such
residues at positions outside of the usual pockets are able to make
energetically favorable contacts because of their large size.
Presumably such peptide residues with few intermolecular
interactions contribute relative little to the overall peptide-MHC
binding affinity so that such docking errors do not dramatically
reduce binding affinity prediction performance.
Peptide-MHC binding affinity predictions
For all allotypes except DRB1*0101, predictions were made for
all peptides in the respective data sets using the Random Forest
classifier trained on DRB1*0101 binding data. Because it was used
for training, the prediction performance for DRB1*0101 was
assessed by 10-fold cross-validation. The prediction performance
results, as measured by the AUC values, for three human allotypes
(DRB1*0101, DQA1*0501/DQB1*0201, and DPA1*0103/
DPB1*0201) and two murine allotypes (H2-IA
b and H2-IA
d) are
shown in Table 3. The corresponding ROC curves for the
relevant low false positive rate range, 0# fpr #0.2, is shown in
Figure 3. The particular allotypes used for testing were chosen for
two reasons: (1) adequate peptide binding data was available for
evaluating the prediction results and (2) they have very different
peptide binding specificities so that the results reflect the generality
of the prediction method for multiple MHC allotypes. As
expected, the prediction performance for DRB1*0101 was quite
high since data for this allotype were used for training. Although
those particular results do not measure the method’s generality,
the results are encouraging since the cross-validation procedure
insured separate training and test data sets. Interestingly, an even
higher accuracy was achieved for DPA1*0103/DPB1*0201,
demonstrating the excellent transferability to a distinct HLA-DP
locus. The high accuracy for this allotype may be related to our
observations that both the RTA (data not shown) and MultiRTA
[30] sequence-based prediction methods yielded generally higher
accuracy for HLA-DP allotypes compared with HLA-DR
allotypes. However, we find no obvious explanation for the higher
HLA-DP prediction accuracy.
Relative contributions of input variables
Although the Random Forest classifier is not readily interpret-
able as is, for example, a linear model, the relative importance of
each input variable to the overall prediction accuracy can be
estimated. This is accomplished by calculating the reduction in the
prediction accuracy for so-called out-of-bag data, not included in
the bootstrap training sample, upon permuting the values for the
variable of interest [42]. The results of this analysis using the
balanced DRB1*0101 data set are shown in Figure 4. This shows
that the empirical and physical interaction energy components
make larger contributions than any of the residue type counts.
This is reasonable on physical grounds since the free energies of
the isolated peptides are partially accounted for by the interaction
energy components in addition to the residue type counts. The
analysis also shows that the van der Waals interactions, which
favor close packing between the peptide and MHC protein, is the
most important energy component. The high importance of the
empirical potentials, which are dominated by hydrophobic van der
Waals interactions, also supports this interpretation.
We also fit a type of generalized linear model, a logistic
regression classifier, to the DRB1*0101 training data using only
the five physical energy components. This was done to obtain an
easily interpretable prediction model in order to examine it in
terms of physical interactions. The optimal weights are shown in
Table 4. One important result is that all weights have the same
correct sign so that favorable interactions for each energy
component contribute to an overall favorable peptide-MHC
binding affinity. Furthermore, all weights were shown to be
statistically significant (at a 5% level), i.e. are expected to be non-
zero and so contribute to the overall prediction.
Peptide binding register predictions
We also compared the predicted predominant peptide binding
register, for which the core peptide had the strongest binding
Figure 3. ROC curves for peptide binding affinity predictions
using the data sets described in Table 3. Only the region with low
false positive rate, which is most relevant in practice, is shown.
doi:10.1371/journal.pone.0014383.g003
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peptide-MHC complexes. This provides an independent test of the
prediction method. The results for individual complexes are shown
in Table 5. Overall, binding registers were correctly predicted for
14/19 (74%) of the human complexes and 12/15 (80%) of the
murine complexes. If restricted only to the cross-docking results
then 6/9 (67%) of the human complexes and 7/10 (70%) of the
murine complexes were correctly predicted.
An analysis of the peptide-MHC complexes with incorrectly
predicted binding registers showed that generally the predicted
binding affinity for the correct register was close to that in the
predicted predominant register (i.e. with highest binding affinity).
Furthermore, although experimental binding affinities are not
available for each individual binding register, they can be
estimated using the RTA sequence-based method [26] for the
allotypes with sufficient available binding data. Two incorrectly
predicted human complexes are covered by the RTA method, the
1AQD peptide binding to DRB1*0101 (1KLU) and the 1FV1
peptide binding to DRB5*0101 (1FV1). Interestingly, RTA
predicts that the binding affinity of the 1AQD peptide in the
incorrectly predicted register (FLRGYHQYA), 10.4 kcal/mol, is
only slightly lower than that in the correct register observed in the
X-ray structure (WRFLRGYHQ), 10.9 kcal/mol. This is a
possible explanation of why the structure-based prediction method
has difficulty determining which of these two registers is the most
stable, particularly since the scoring method was trained on RTA
predictions for this allotype. It also suggests that the 1AQD peptide
may in fact have two alternative binding registers for DRB1*0101,
with the observed register favored by the crystallization environ-
ment. Such multiple binding registers have been computationally
predicted to be fairly prevalent in strong binders [26,34] and have
also been experimentally observed [48,49,50]. The RTA results
for the 1FV1 peptide binding to DRB5*0101 shows a similar
trend, with the binding affinity of the incorrectly predicted register
(VHFFKNIVT), 8.76 kcal/mol, the second highest just after the
correct register (FKNIVTPRT), 10.5 kcal/mol, although the
affinity difference is greater than for 1AQD. Interestingly, the
prediction accuracy for the peptide binding register did not seem
to be significantly correlated with the docking accuracy. This is
consistent with the above observation that the largest docking
errors can be attributed to residues with large side chains that have
few contacts with the MHC protein and so are unlikely to have a
significant effect on the binding affinity prediction accuracy.
Comparison to sequence-based approaches
The recent study by Zhang et al. [35] evaluated three different
structure-based epitope prediction methods on a set of peptides
binding to DRB1*0101 and arrived at a rather pessimistic view of
such ab initio methods, which do not make use of any experimental
peptide-MHC binding data. This conclusion was based on the
observation that all three methods achieved results that were
significantly better than random but still were substantially lower
than the best performing sequence-based methods. Our prediction
method would not be considered as ab initio by the definition used
in that study, since the scoring method is parameterized using
experimental binding data, albeit for an MHC allotype with
completely different peptide binding preferences. We were able to
perform a similar comparison to prediction results from our
MultiRTA sequence-based method [30] for the two MHC
allotypes covered by the HLA-DR and HLA-DP models. In order
to avoid overfitting, binding data for the MHC allotype of interest
was omitted from the training data used to fit the MultiRTA
prediction model. The results for the DRB1*0101 and
DPA1*0103/DPB1*0201 data sets are presented in Table 6.A s
expected, the AUC values for the MultiRTA sequence-based
method, shown in Table 6, are higher than the corresponding
values for the structure-based method, shown in Table 3,
indicating its higher accuracy for these three allotypes. We next
discuss the implications of these results for the structure-based and
sequence-based approaches to epitope prediction.
Discussion
The prediction results for a diverse set of representative class II
MHC allotypes demonstrate that our method can discriminate
binders from non-binders and supports the generality of the
structure-based approach to epitope prediction. As in the recent
Figure 4. Relative importance of the Random Forest input
properties to the overall binding affinity prediction accuracy.
These results show that the interaction energy terms contribute the
most to the prediction performance.
doi:10.1371/journal.pone.0014383.g004
Table 4. Logistic regression coefficients for a model trained
only on DRB1*0101 binding energy components.
Variable Coefficient value (standard error) Significance
DEvw 20.112 (0.00838) ,2.0610
216
DEhb 20.108 (0.0143) 3.7610
214
DEel 20.0203 (0.0102) 4.7610
22
DEen 20.643 (0.0482) ,2.0610
216
DEsf 20.339 (0.0546) 5.0610
210
Intercept 210.1 (0.844) ,2.0610
216
All coefficients are statistically significant (p,5%) and are negative, as expected
from physical considerations.
doi:10.1371/journal.pone.0014383.t004
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performance of the structure-based approach is generally lower
than that of sequence-based approaches. This should be expected
considering that sequence-based methods generally rely on far
more input parameters than structure-based methods in order
make binding predictions and also are directly fit to experimental
binding data for a similar or identical MHC allotype. For example,
the structure-based method presented here uses 27 input
parameters for scoring whereas a PSSM sequence-based approach
potentially has up to 180 parameters and multi-allotype models,
such as NetMHCIIpan and MultiRTA, have even more
parameters. Furthermore, the sequence-based results were ob-
tained using prediction models that were trained on binding data
for MHC types whose peptide binding preferences are similar
enough that even a prediction model trained only on data for the
Table 5. Peptide binding register predictions compared with all human and mouse peptide-MHC X-ray structures.
MHC allotype
MHC PDB
entry
Peptide PDB
entry Peptide sequence
Rank of core segment/
Number of core segments
DRB1*0101 1KLU 1KLU* GELIGTLNAAKVPAD 1/7
DRB1*0101 1KLU 1AQD VGSDWRFLRGYHQYA 2/7
DRB1*0101 1KLU 1DLH, 2G9H PKYVKQNTLKLAT 1/5
DRB1*0101 1KLU 1KLG GELIGILNAAKVPAD 1/7
DRB1*0101 1KLU 1SJE PEVIPMFSALSEGATP 1/8
DRB1*0101 1KLU 1T5W AAYSDQATPLLLSPR 1/7
DRB1*0101 1KLU 2FSE AGFKGEQGPKGEPG 1/6
DRB1*0301 1A6A 1A6A* KPKPPKPCSKMRMATPLLMQALPM 1/16
DRB1*0401 1J8H 1J8H* PKYVKQNTLKLAT 1/5
DRB1*0401 1J8H 2SEB QYMRADQAAGGLR 2/5
DRB1*1501 1BX2 1BX2* ENPVVHFFKNIVTPR 1/7
DRB3*0101 2Q6W 2Q6W* AWRSDEALPLGS 1/4
DRB5*0101 1FV1 1FV1* NPVVHFFKNIVTPRTPPPSQ 3/12
DRB5*0101 1FV1 1H15 GGVYHFVKKHVHES 1/6
DQA1*0501/DQB1*0201 1S9V 1S9V* QLQPFPQPELPY 1/4
DQA1*0102/DQB1*0602 1UVQ 1UVQ* MNLPSTKVSWAAV 1/5
DQA1*0301/DQB1*0302 2NNA 2NNA* QQYPSGEGSFQPSQENPQ 2/10
DQA1*0301/DQB1*0302 2NNA 1JK8 SHLVEALYLVCGERG 5/7
DPA1*0103/DPB1*0201 3LQZ 3LQZ* RKFHYLPFLPST 1/4
H2-IA
b 1MUJ 1MUJ* PVSKMRMATPLLMQA 1/7
H2-IA
b 1MUJ 1LNU FEAQKAKANKAVD 1/5
H2-IA
d 2IAD 1IAO ISQAVHAAHAEI 1/4
H2-IA
g7 1ES0 1ES0* YEIAPVFVLLEYVT 1/6
H2-IA
g7 1ES0 1F3J AMKRHGLDNYRGYSL 1/7
H2-IA
g7 1ES0 3CUP KKMREIIGWPGGSGG 1/7
H2-IA
k 1IAK 1IAK* TDGSTDYGILQINSRW 1/8
H2-IA
u 1K2D 1K2D* SRGGASQYRPSQR 1/5
H2-IE
k 1FNG 1FNG* GKKVITAFNEGLK 1/5
H2-IE
k 1FNG 1FNE GKKVITAFNDGLK 1/5
H2-IE
k 1FNG 1IEB RDRMVNHFIAEFK 1/5
H2-IE
k 1FNG 1KT2 RDLIAYLKQATK 2/4
H2-IE
k 1FNG 1KTD RDLIAYLKQASAK 2/5
H2-IE
k 1FNG 1R5V ADLIAYPKAATKF 1/5
H2-IE
k 1FNG 1R5W ADLIAYFKAATKF 2/5
Asterisks indicate self-docking results. The core segment is underlined in the peptide sequence.
doi:10.1371/journal.pone.0014383.t005
Table 6. MultiRTA sequence-based prediction results for the
same data sets used to obtain the structure-based prediction
results in Table 3.
AUC
MHC allotype Peptide
Estimated
Core 1
Estimated Core
1–2
DRB1*0101 0.782 0.931 0.910
DPA1*0103/DPB1*0201 0.929 0.988 0.985
The estimated core AUC values were obtained as described in the Table 3
caption and the Methods section.
doi:10.1371/journal.pone.0014383.t006
Universal Epitope Prediction
PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e14383single closest allotype attains relatively high accuracy [29,30].
Most importantly, although the structure-based approach cannot
attain the level of accuracy of the best sequence-based methods,
they are able to predict epitopes for MHC allotypes remotely
related to allotypes with experimental binding data. Even in
principle, this is impossible for a purely sequence-based method.
Furthermore, the sequence-based methods that make limited use
of structural information, such as peptide-contacting polymorphic
MHC residues for NetMHCIIpan [29] and MultiRTA [30] or
MHC pockets for TEPITOPE [28], can only interpolate to MHC
allotypes that largely share the same MHC polymorphic residues
or pockets as experimentally characterized MHC allotypes but in
different combinations. For example, the 14 HLA-DR allotypes
with sufficient experimental binding data allow fitting a sequence-
based model that covers most of the HLA-DR allotypes [29,30],
however these data cannot be used to make predictions for any
HLA-DQ allotype, for which little experimental data is available.
In summary, each class of prediction method has its optimal
domain of applicability. Sequence-based methods should be used
for MHC allotypes similar to those that have been experimentally
characterized, such as most HLA-DR allotypes. On the other
hand, only structure-based methods can currently be used for the
large number of remaining allotypes, including almost all of those
for HLA-DP, HLA-DQ, and non-human allotypes.
We also derived a rough quantitative estimate of the epitope
prediction accuracy for individual 9-mer core segments. Unlike for
class I MHC, in which a peptide has only a single binding mode, a
peptide can generally bind to class II MHC in multiple binding
registers, each defined by which 9-mer segment of the complete
peptide contacts the central portion of the binding cleft in the
MHC protein. This additional degree of freedom, which cannot
be directly ascertained from experimental peptide binding data,
makes epitope prediction for class II MHC more difficult than for
class I MHC. This is reflected in the generally lower performance
of class II MHC prediction methods compared with those for class
I MHC, regardless of whether they are sequence-based or
structure-based. Using a similar structure-based approach for
class I MHC epitope prediction, we previously obtained an AUC
of 0.85 for epitope prediction for a H2-K
b murine MHC allotype
that is highly dissimilar to the human HLA-A*0201 allotype used
for training [36]. This AUC value is comparable to the estimated
core AUCs in the last column of Table 3. In other words, the
accuracy for predicting whether or not a peptide binds in a single
particular conformation is roughly similar for both class I and class
II MHC so that the lower accuracy for class II MHC is
predominantly due to an accumulation of errors resulting from
the multiple possible peptide binding registers. This suggests a
promising application of the structure-based method, discovering
strongly binding 9-mer core fragments for uncharacterized MHC
allotypes. Presumably the prediction performance would be higher
for these fragments because they can only bind in one register. The
predicted 9-mer epitopes could then be extended by additional N-
and C-terminal residues and experimentally validated.
There are many possible directions for future work. One of the
most important is to investigate epitope prediction using homology
models of class II MHC allotypes without available X-ray
structures in the PDB. Currently, X-ray structures are only
available for the human and murine allotypes listed in Tables 1
and 2. Different class II allotypes share close sequence identities
and relatively conserved backbone structures so that this should be
straightforward. The main challenge will be to accurately predict
the conformations of the MHC residues that contact the peptide,
particularly if a rigid model of the MHC is employed for docking.
Several previous studies have investigated class II MHC homology
models and their use in docking [32,51,52]. Also it is important to
attempt to speed up the epitope prediction method. Because we
did not attempt to minimize the docking simulation length, it may
be possible to significantly reduce it without sacrificing accuracy.
Another possible approach is to fit a PSSM to structure-base
prediction results for a series of all possible single residue mutants
of a strong binding peptide. One other possible improvement is to
incorporate MHC flexibility by sampling peptide-contacting
MHC residue rotamer conformations or utilizing multiple
alternative rigid models of the binding cleft in the docking
procedure. Additionally, explicitly accounting for water molecules
that have been observed in the peptide-MHC interface [53,54,55]
may further increase modeling accuracy. Furthermore, as
mentioned above, incorporating additional flanking peptide
residues in the docking and scoring may improve prediction
accuracy. This is supported by observed atomic contacts between
flanking residues and the MHC in peptide-MHC complex X-ray
structures and improvements in sequence-based epitope prediction
methods upon incorporating information on these residues
[27,56]. Adding flanking residues in the docking procedure is
straightforward but will increase the simulation convergence time.
Also the higher variability in the peptide backbone outside of the
central 9-mer core observed in X-ray structures of peptide-MHC
complexes implies that these residues will be more difficult to
model correctly. It is also worthwhile exploring methods to directly
fit the scoring method to experimental peptide-MHC binding
affinities rather than relying on error-prone sequence-based
prediction results. Finally, one potentially useful application that
is well suited to a structure-based approach is to predict peptide
epitopes with posttranslational modifications. Experimental evi-
dence indicates that such peptides bind to class II MHC and may
have a role in autoimmunity [57,58].
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